STOCKHOLM, SE / ACCESSWIRE / May 17, 2022 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
Today, 17 May 2022, the annual general meeting was held in AlzeCure Pharma AB (publ). Below is a summary of the resolutions made. All resolutions were passed with the required majority.
Resolution on the establishment of accounts and disposal of the company's result
The annual general meeting resolved to establish the income statement and the balance sheet. The annual general meeting also resolved to dispose the company's result in accordance with the board of directors' and the CEO's proposal, meaning that no dividend is paid to the shareholders, and that available funds are carried forward.
Discharge for members of the board of directors and the managing director
The annual general meeting resolved to grant discharge to the members of the board of directors and the managing director for the financial year 2021.
Election of and remuneration to the board of directors and the auditor
The annual general meeting resolved, in accordance with the nominating committees' proposal, on re-election of Thomas Pollare, Ellen Donnelly, Ragnar Linder and Eva Lilienberg as ordinary members of the board of directors. Thomas Pollare was re-elected as chairman of the board of directors.
The annual general meeting further resolved that the remuneration to the board of directors shall be SEK 200,000 to the chairman and SEK 100,000 to each of the other board members who are not employed by the company.
The annual general meeting also resolved to re-elect Grant Thornton AB as auditor and that the auditor shall be paid according to approved invoice. Grant Thornton AB has announced that the certified accountant Camilla Nilsson will be the auditor in charge.
Resolution on the approval of the remuneration report
The annual general meeting resolved to approve the board of director's remuneration report in accordance with Chapter 8, Section 53 a of the Swedish Companies Act.
Authorisation for the board of directors to resolve on new issues
The annual general meeting resolved, in accordance with the board of directors' proposal, to authorise the board of directors, on one or more occasions during the period until the next annual general meeting, with or without deviation from the shareholders' pre-emptive right, to resolve on new issues of shares, warrants and/or convertibles that means issuing, subscribing to or converting a number of shares corresponding to a maximum dilution of 20 per cent of the total number of shares in the company at the time of the resolution. The new issues can be carried out with or without a provision regarding contribution in kind, set-off or other provisions referred to in Chapter 13, Section 5, first paragraph 6, Chapter 14, Section 5, first paragraph 6 and Chapter 15, Section 5, first paragraph 4, of the Swedish Companies Act.
The purpose of the authorisation is to increase the company's financial flexibility and the board of directors' scope of action.
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative small molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets other types of severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase and is continually working on business development to find suitable solutions for license agreements with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 firstname.lastname@example.org, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se
SOURCE: AlzeCure Pharma
View source version on accesswire.com: